Genomic Health's Q2 Revenues Rise 32 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market Tuesday that its second-quarter revenues increased 32 percent on increased sales of its Oncotype Dx breast cancer test.

The Redwood City, Calif.-based pharmacogenomic test developer and service provider brought in total revenues of $36.6 million, up from $27.8 million for the second quarter of 2008. Product revenue from Oncotype Dx was $35.2 million, an increase of 34 percent over revenue of $26.3 million for the comparable period of 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.